Allocation of Regulatory Responsibilities: Who Will Balance Individual Rights, the Public Interest and Biobank Research Under the GDPR?

Jane Reichel

Abstract In this chapter, an analysis is undertaken of the division of legislative power in the space created by the GDPR, regarding the balancing of individual rights, the public interest and biobank research. The legislative competences of the EU, international obligations within bioethics, and the regulatory space left for Member States are all examined. The conclusion of the chapter is that in spite of the aim of the GDPR to further legal harmonisation, it is more likely that unity will be brought about through administrative cooperation and soft law tools.

1 Introduction: Balancing Individual Rights and Public Interest in Biobank Research Post-GDPR

Balancing the individual right to data protection and the public interest in biobank research involves a number of constitutional and statutory rules within the EU. The individual right to data protection enjoys a strong constitutional protection within the EU legal order, being included both in Article 8 of the EU Charter of Fundamental Rights (Charter) and Article 16 of the Treaty of the Functioning of the European Union (TFEU). The General Data Protection Regulation (GDPR) further provides a comprehensive set of legislation on how the right is to be upheld in practice, according to what the EU refers to as ‘a gold standard’. Research also benefits from some protection since freedom of science is protected in several international treaties. The 1948 Universal Declaration on Human Rights includes a right to share in scientific advancements and benefits, although this is not exactly directed at research itself. The International Covenant on Economic, Social and Cultural Rights contains an

1 Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (GDPR) and Slokenberga et al. (2019), p. 32.
obligation on the Member States to ‘respect the freedom indispensable for scientific research and creative activity’. The EU Charter declares in Article 13 that arts and scientific research shall be free of constraint. Framed like this, freedom of science can hardly be said to be an individual right that researchers can rely on, but nevertheless it does represent recognition of the importance and value of science.2

The protection of individual rights is, however, not the only objective of the GDPR. According to Article 1, the GDPR has as its dual aim to protect natural persons with regard to the processing of personal data and provide rules relating to the free movement of personal data.3 Within the understanding of free movement of personal data also lies the possibility to use the data for different aims, such as research. The tension between these aims and objectives has been analysed throughout this book.

One of the more salient aims of the EU’s data protection law reform which led to the enactment of the GDPR was to diminish the discrepancies between national laws implementing the EU Data Protection Directive.4 For the biobank community, this step was more than welcome. The fragmentation of European biobanking law has been identified as a major hurdle to prosperous biobank research.5 In a report on the subject commissioned by the EU Commission in 2012, the first recommendation out of nine was the following:6

Member states and European institutions should develop a consistent and coherent legal framework for biobanking that should protect participants’ fundamental rights, in particular in the areas of privacy, data protection and the use of human tissue in research.

The legislative form of the GDPR, a regulation instead of a directive, was chosen in order to ensure that the same law would be applicable throughout the EU. In Recital 10 of the GDPR it is stated that ‘(c)onsistent and homogenous application of the rules for the protection of the fundamental rights and freedoms of natural persons with regard to the processing of personal data should be ensured throughout the Union’. As has been widely discussed, and is also apparent from the contributions in this book, in the area of scientific research, this objective has only been partially achieved. In the same recital it is also stated that ‘(t)his Regulation also provides a margin of manoeuvre for Member States to specify its rules, including for the processing of special categories of personal data (“sensitive data”)’. In this

2 Ruffert and Steinecke (2011), p. 30.
3 See Article 1 GDPR which defines the dual objective of the regulation as protection of natural persons with regard to the processing of personal data and rules relating to the free movement of personal data. It may further be reiterated that the Directive 95/46/EC of the European Parliament and of the Council of 24 October 1995 on the protection of individuals with regard to the processing of personal data and on the free movement of such data, the Data Protection Directive, was enacted as an internal market instrument, under Article 100a Treaty establishing the European Community (today Article 114 TFEU).
4 Recital 9 and 13 GDPR.
5 Gottweis et al. (2012), p. 8. See, for a global perspective, Dove (2015), p. 681.
6 Gottweis et al. (2012), p. 6.
way, the GDPR offers considerable room for inconsistencies at the individual proj-
ec-t and Member State levels.

The core data protection principles are laid down in the GDPR, but the detail, the
prerequisite for performing the balancing test between individual right and public
inter-e-st in biobank research, is defined in the laws of the Member States. What does
this mean for biobankers in the EU, and for biobank networks, such as the BBMRI-
ERIC? A central question is thus the relationship between the core principles and
the details in the derogations. How far does the regulatory space of the Member
States reach when implementing the research exceptions? In the Schrems case the
Court of Justice of the European Union (CJEU) held there limits to how far restric-
tions on the individual right to privacy, in this case based on Article 7 of the Charter,
could go; restrictions may not compromise ‘the essence of the fundamental right to
respect for private life’. These boundaries are to be upheld also by the Member
States. The question, thus, is how a legitimate and foreseeable regulatory regime
for processing of health data in biobanking is to be achieved. Does the GDPR con-
tain mechanisms that provide a level playing field for biobanks within the EU today?

The analysis in this chapter draws on the conclusion presented in this book, in an
effort to answer these questions. In Sect. 2, the background to the diversity in the
regulatory landscape was analysed from the perspective of legislative competence
of the EU. In Sect. 3, the outcome of the implementation of the GDPR in the
Member States was discussed. In Sect. 4, the potential consequences of the differ-
ences in regulatory regimes were addressed in relation to forum shopping, and Sect.
5 did the same in relation to administrative cooperation and soft law tools for har-
monisation. In the final Sect. 6, the question of how a level playing field for bio-
banks can be achieved is discussed.

2 Diversity in Regulatory Responses to the GDPR
in the Member States

2.1 Components for Regulating the Processing of Personal
Data in Biobank Research

There are two core principles in the law and ethics of biomedical research that can
be considered to be universally accepted: in all bio-scientific research activity the
principle of informed consent of the individual involved must be respected, and all
bio-medical research should be reviewed by research ethics committees before

7 Case C-362/14 Schrems v Data Protection Commissioner, EU:C:2015:650, p. 94.
8 See Joined Cases C-203/15 and C-698/15 Tele2 Sverige AB v Post- och telestyrelsen and
Secretary of State for the Home Department v Tom Watson, Peter Brice, Geoffrey Lewis,
EU:C:2016:970, p. 129.
being conducted. These principles have also gained an increasing acceptance in connection to processing of personal data in research. However, at the global level, there is still no legally binding document regulating these issues.

As has been discussed throughout this book, and in line with the GDPR, processing of personal data can be lawfully conducted based on either informed consent or public interest, legitimate interest, contract, etc. If the personal data belong to a special category, for example, health data or genetic data, further requirements set forth in Article 9 apply. According to Article 9(2)(j) and Article 89, this type of data may be processed in research under the condition that there are appropriate safeguards available, normally via ethical approval from research ethics committees. The value of research will thus be balanced against the risk of harm from privacy intrusion experienced by data subjects. Regulating the processing of personal data in biobank research therefore involves at least three separate regulatory areas: data protection, research and bioethics.

### 2.2 EU Regulatory Competences in Data Protection, Research and Bioethics

As discussed previously in this book, the regulatory competence of the EU is central to the understanding of the regulatory regime for the processing of personal data in research. In contrast to national states, the EU does not have a general legislative competence but may only enact binding law in areas where the Member States have conferred powers to legislate. This notion is generally referred to as the principle of conferral and is codified in Article 5(2) of the Treaty of the European Union.

In regards to data protection, the question is unproblematic. With the Lisbon Treaty the EU was conferred a specific competence in the area of data protection in Article 16(2) TFEU. According to the Article, the EU may enact ‘rules relating to the protection of individuals with regard to the processing of personal data’ and ‘rules relating to the free movement of such data’. The EU also has some competence in the area of research, but it is limited in several ways. The EU may, for example, carry out activities to define and implement programmes and set up joint

---

9 Ruffert and Steinecke (2011), pp. 94–96.
10 Slokenberga et al. (2019), p. 32.
11 Article 6(1) GDPR.
12 Article 9(2)(J) and Article 89(1) GDPR and the contributions to this book.
13 See the chapter by M.G. Hansson in this book, and Whitley (2016) p. 39.
14 See the chapter by S. Slokenberga in this book.
15 See further Reichel (2016), p. 174.
16 The previous Data Protection Directive was enacted as an internal market act, under Article 100 a Treaty establishing the European Community (EC) at the time of the enactment of the Directive, today Article 114 TFEU.
undertakings or any other structure necessary for the efficient execution of Union research, technological development and demonstration. One example of the latter is the regulation introducing a procedure for Member States to establish a European Research Infrastructure Consortium (ERIC), under which the BBMRI-ERIC was established. However, when it comes to ethical issues, the EU does not have any competence to enact legislative acts.

Even though the lack of sufficient legislative competence to fully regulate the processing of health or genetic data in biobank research arguably could have been overcome through an extensive interpretation of the competence to regulate data protection issues, as has been done in the area of administrative cooperation, which is another area where the EU has only limited competence to regulate, the strong connection between governance of research and bioethics and national legal culture may have made it politically impossible. Moreover, even though the underlying values and ideas of the bioethical aspects of law can to a large extent be described as universal, there are still national and regional differences, not least when it comes to health and genetics. The differences in the regulatory responses of the Member States, discussed throughout this book, seem to confirm this.

2.3 Aligning the GDPR with Other International Obligations of the Member States

One central regulatory aspect of biobank research is the definition of informed consent. The GDPR permits using what is known in research circles as ‘broad’ consent. However, as noted several times throughout this book, consent in itself is not a

---

17 Article 179 and 187 TFEU.
18 Council regulation (EC) No 723/2009 of 25 June 2009 on the Community legal framework for a European Research Infrastructure Consortium (ERIC).
19 See, for example, the Amended Proposal for a Directive of the European Parliament and of the Council on Setting Standards of Quality and Safety for the Donation, Procurement, Testing, Processing, Storage, and Distribution of Human Tissues and Cells, COM (2003) 340 final, p. 4, where the Commission rejected certain proposals from the European Parliament on ethical issues on the grounds that Article 168 TFEU, which at the time was Article 152 EC, does not give the EU competence in that field. See further Busby et al. (2008).
20 The GDPR contains elaborated rules on administrative governance and cooperation, which will be discussed briefly in Sect. 3. Further, in regards to clinical trials, the EU has adopted certain rules on administrative cooperation in bioethical matters, Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use and the European Data Protection Board issued Opinion No 3/2019 which concerns the interplay between the EU Clinical Trials Regulation (CTR) and the GDPR.
21 For example, Article 23.1 World Medical Association, Declaration of Helsinki—Ethical Principles for Medical Research Involving Human Subjects holds that the law of the land is to be applied, together with relevant international norms and standards as long as these do not undermine the Helsinki Declaration itself.
necessity for personal data to be lawfully processed. In that way, the GDPR paves a rather smooth path for research on residual samples and data. In itself, this approach is not novel. It has previously existed in different national legal orders, as well as internationally. For example, when referring to the collection of human specimens, Article 22 of the Biomedicine Convention states:

When in the course of an intervention any part of a human body is removed, it may be stored and used for a purpose other than that for which it was removed, only if this is done in conformity with appropriate information and consent procedures.

In the explanatory report to the convention it is noted that an appropriate information and consent procedure does not necessarily mean that the patient or his or her representative must give a formal informed consent. It indicates that ‘[i]n some cases, it will be sufficient for a patient or his or her representative, who have been duly informed (for instance, by means of leaflets handed to the persons concerned at the hospital), not to express their opposition’.22 The GDPR addresses the information requirement in this regard under Article 14, allowing exceptions if ‘the provision of such information proves impossible or would involve a disproportionate effort’.23

From this, the question emerges whether the EU has attempted to re-define the minimum level of protection for individuals when research concerns their residual biological material. If so, this creates a conflict of laws between the Council of Europe and the EU legal orders, and it is questionable whether those Member States of the EU that have ratified the Biomedicine Convention will be able to take full advantage of what the GDPR offers. Additional questions can be raised regarding those states that have signed the convention only, and are thus obliged not to defeat the object and purpose of the treaty. A solution here could be found in Article 26 of the Biomedicine Convention which does not place Article 22 in the cluster of core values of the convention, and thus permits the state parties to restrict these rights in some situations.

However, from an ethical standpoint and at least on the surface, this can be seen as rather problematic. The control expressed by the research participant/data subject through the possibility to decide on whether or not to participate in a particular study may not necessarily relate to the desire to control personal data. As noted by Staunton et al., it may well be attributed to the aim of the particular study and an unwillingness of the research participant/data subject to have their data used in studies that do not conform to their ethical beliefs.24 Has the GDPR therefore stripped the data subjects of their ability to control the use of their data in research? In our view, as expressis verbis stated in Article 9(2)(j), it is in the hands of the Member States and the EU. The ability to avoid consent-based research has been subordinated to the EU competence

---

22 Explanatory Report—ETS 164—Human Rights and Biomedicine (Convention), https://rm.coe.int/16800ccee5, para 137.
23 Art 14(5)(b) GDPR.
24 Staunton et al. (2019), p. 2.
limitations and prevailing values in a particular national legal order. It may well be
the case that a particular Member State will choose not to operationalise Article 9(2)
(j) GDPR, but up until now, at least according to the country laws that have been
reviewed in this book, this approach has not been taken.

3 Regulating Safeguards at the National Level:
Heterogeneity Remains

Article 89(1) and (2) divides the responsibility for ensuring that appropriate condi-
tions and safeguards are in place for the lawful processing of personal data in
research between the EU and the Member States. The first paragraph, Article 89(1),
does not clearly point out who is responsible for ensuring safeguards but merely
holds that ‘processing for (…) scientific or historical research purposes (…), shall
be subject to appropriate safeguards, in accordance with this Regulation, for the
rights and freedoms of the data subject’. Safeguards may be provided via national
law, but it is required that they are regulated ‘in accordance this Regulation’, the
GDPR. Article 89(2), on the other hand, refers to either Union law or national law
to allow derogations from Articles 15, 16, 18 or 21, subject to appropriate condi-
tions and safeguards.25 Accordingly, the conditions and safeguards for processing
personal data in biobank research are regulated in a decentralised manner. Also,
Article 9(4) GDPR contributes to the decentralisation by allowing Member States to
maintain or introduce further conditions, including limitations for the processing of
genetic data, biometric data or data concerning health. In addition, Article 23 GDPR
allows for further general derogations in the public interest, for example, for public
health.26

As the pan-European survey by Tzortztou et al. in chapter ‘Biobanking Across
Europe Post-GDPR: A Deliberately Created Fragmented Landscape’ in this book
illustrates, the Member States have taken different approaches in implementing these
conditions and safeguards in regard to both the form and content. Whilst Sweden has
taken a minimalistic approach and has only made use of the possibility in Article
89(2) GDPR to adopt general derogations in a limited manner, the regulatory frame-
work for allowing researchers to access and process data held in public population-
based health registries remains wide.27 In Italy, the entry into force of the GDPR has,
on the other hand, had the function of filling the gap in the legislation with regard to
biobanking for medical scientific research purposes.28 In France and in Finland, the

25 See the chapter by A.G. Duguet and J. Herveg in this book for further details.
26 The concept of public interest in the GDPR is analysed by S. Slokenberga, see the chapter by
S. Slokenberga in section 4.3.4 in this book.
27 See the chapter by M. Stenbeck, S. Eaker Fält and J. Reichel in this book.
28 See the chapter by S. Penasa and M. Tomasi in this book, section IV.
national regulatory approach seems to a certain extent to uphold a stricter standard than required by the GDPR, whereas in Estonia, the legislator has chosen a more lenient approach.\textsuperscript{29} The national regulatory responses thus remain heterogeneous.

4 Addressing Regulatory Differences Via Forum Shopping?

A relevant question to pose is whether this heterogenous regulatory landscape may lead to forum shopping, in the sense that research proposals are allocated to Member States with the most beneficial regulatory regimes. The question of forum shopping, or in other words, regulatory competition, is far from unknown in the EU Internal Market and not always seen as problematic in itself. Within the Internal Market, Member States should allow a free flow of goods, services, labour and capital, unless there is a legitimate reason to hinder it.\textsuperscript{30} It is for the economic actors in the Internal Market to allocate their business to the forums that offer the most advantageous conditions. In the \textit{Centros} case, the CJEU held that it was contrary to the rules of the Internal Market for a Member State to refuse to register a ‘letterbox-company’ merely on the basis that the company wanted to allocate its business in a less restrictive regulatory environment. Only on suspicion of fraud would it be legitimate for the Member State to take action.\textsuperscript{31} The practice is also well known in labour law where employers might want to place their headquarters in a state with a more lenient labour law regime. Even if this is often criticised, it has proven difficult to combat the practice without distorting the Internal Market.\textsuperscript{32} As mentioned in the introduction, the GDPR has as its objective to promote free movement of personal data. In global medical research, the concepts of ‘ethics dumping’, the practice of exporting unethical research practices to lower-income settings, has been recognised as an ethical problem.\textsuperscript{33} The differences between Member States of the EU should not be exaggerated, but at the same time researchers allocating research proposals to certain states in order to circumvent ethical regulation can be seen as problematic and will in the long run undermine social trust in biobanking. The next issue to consider is therefore whether the GDPR contains any mechanisms that may bridge the regulatory differences.

\textsuperscript{29}See the chapter by G. Chassang et al., section 5.1; Chapter by T. Southerington, section III and chapter by K. Pormeister, section 4.

\textsuperscript{30}Article 26 TFEU.

\textsuperscript{31}Case C-212/97 Centros Ltd v Erhervs- og Selskabsstyrelsen EU:C:1999:126, p. 39.

\textsuperscript{32}Houwerzijl (2014), p. 98.

\textsuperscript{33}See, for example, The Global Code of Conduct for Research in Resource-Poor Settings, in particular Article 14. The code was developed within the TRUST, Equitable research party projects, see further www.globalcodeofconduct.org/.
5 Addressing Regulatory Differences Via Administrative Cooperation and Soft Law Tools

As mentioned briefly above and as also discussed by Dara Hallinan in chapter ‘Biobank Oversight and Sanctions Under the General Data Protection Regulation’ of this book, the GDPR contains an elaborated governance structure for both European and national administration within the data protection area. Here, focus is laid on the potential of this structured cooperation of authorities to overcome differences in interpretations of data protection rules and concepts. It is in this context of interest to note that the administrative structure is partially regulated also in EU primary law. Both Article 8 of the Charter and Article 16 TFEU state that compliance with data protection rules shall be subject to control by an independent authority. This independency is regulated in Chapters VI and VII of the GDPR, together with the competence, tasks and powers of the national data protection authorities (DPAs) and the newly established European Data Protection Board (EDPB), which has taken over after the previous Article 29 Working Party Group.

One of the tasks of the EDPB is to issue guidelines, recommendations, best practices and opinions on a wide range of subjects.34 Even if the GDPR does not regulate biobanking directly, these documents will often be relevant both in regards to defining core principles of data protection, such as informed consent, and in relation to processing personal data across sectors, such as clinical trials.35 The GDPR also introduced several new tools with which DPAs can cooperate; two of these will be discussed here. These are a one-stop-shop mechanism for appointing a lead authority in cases involving monitoring of cross-border processing and a procedure for composite decision-making, labelled a consistency mechanism.36

The first mechanism was established to offer a smooth and foreseeable means of supervision since it identifies one single DPA to act as a one-stop-shop for controllers and processors active in more than one Member State, thus giving the lead DPA a role as coordinator of the supervision of all the processing activities of that business throughout the EU in collaboration with other ‘concerned’ DPAs.37

The second, the consistency mechanism, provides a procedure for fulfilling the role of a dispute resolution mechanism in which the EDPB functions as a dispute resolution body.38 According to this procedure, a DPA can refer a draft decision to

---

34 Article 70(1) GDPR.
35 See European Data Protection Board, Guidelines on Consent under Regulation 2016/679 (wp259rev.01) and European Data Protection Board, Opinion No 3/2019 which concerns the interplay between the EU Clinical Trials Regulation (CTR) and the GDPR. Further, the European Data Protection Supervisor (EDPS), tasked with monitoring data protection within the EU institutions and bodies under Regulation 2018/1725, has issued a Preliminary opinion on data protection and scientific research, 6 January 2020.
36 Article 56 and 63–66 GDPR, respectively. See further Hijmans (2016), p. 369.
37 Article 60 GDPR and Giurgiu and Larsen (2016), p. 349.
38 Ibid, p. 350.
the EDPB before enacting a decision in different categories of situations. In the first category, consisting of six identified cases, referral is compulsory.39 In the second category, concerning ‘any matter of general application or producing effects in more than one Member State’, referral is optional.40 However, the procedure in the second paragraph can be initiated by any DPA, not merely the lead authority, the chair of the EDPB and the Commission. If the DPAs cannot agree, any one of them may trigger the consistency mechanism, thus inviting the EDPB to take a leading role. In both categories, the EDPB issues an opinion which all DPAs and the Commission may comment on.41 The lead authority must ‘take utmost account of the opinion of the Board’ and communicate to the Chair of the Board whether it will maintain or amend its draft decision.42 If the lead authority does not abide by the opinion, the EDPB may proceed with a dispute resolution. This effectively entails a decision adopted for the individual case which the DPA must implement by giving a final decision according to the requirements of the relevant national law, referring to the decision enacted by the EDPB.43 If and to what extent this mechanism is to be used within the area of research in general or biobank research in particular remains to be seen. Within the areas where the GDPR acknowledges the regulatory competence of the Member States, such as due to the research exceptions, it is hardly conceivable that the consistency mechanism can reconcile the various approaches and traditions of the Member States, at least not in a comprehensive manner.

A more customised tool for defining the proper balance between individual right and public interest in biobank research is the code of conduct.44 A code of conduct can be drafted by private companies and organisations for the processing of personal data by certain categories of controllers or processors.45 The procedure for adopting a code of conduct involves both a DPA, the EDPB and the Commission, and results in a binding document specifying the proper application of the GDPR for processing within the Union and as a basis for transfer outside.46 In June 2019,

39 According to Article 64(1) GDPR, the competent supervisory authority shall communicate the draft decision to the Board when it: (a) aims to adopt a list of the processing operations subject to the requirement for a data protection impact assessment pursuant to Article 35(4); (b) concerns a matter pursuant to Article 40(7) whether a draft code of conduct or an amendment or extension to a code of conduct complies with this Regulation; (c) aims to approve the requirements for accreditation of a body pursuant to Article 41(3), of a certification body pursuant to Article 43(3) or the criteria for certification referred to in Article 42(5); (d) aims to determine standard data protection clauses referred to in point (d) of Article 46(2) and in Article 28(8); (e) aims to authorise contractual clauses referred to in point (a) of Article 46(3); or (f) aims to approve binding corporate rules within the meaning of Article 47.

40 Article 64(2) GDPR.
41 Article 64(4) GDPR.
42 Article 64(7) GDPR. See further Recital 136 GDPR.
43 Article 65 GDPR.
44 Also, the Data Protection Directive recognised code of conducts, Article 27.
45 Article 40 GDPR.
46 Article 40(2) and 46(2) (e) GDPR.
the EDPB issued guidelines on the subject.\textsuperscript{47} These describe the codes as being able to ‘help to bridge the harmonisation gaps that may exist between Member States in their application of data protection law’, and to ‘provide an opportunity for specific sectors to reflect upon common data processing activities and to agree to bespoke and practical data protection rules, which will meet the needs of the sector as well as the requirements of the GDPR’.\textsuperscript{48}

The BBMRI-ERIC is currently drafting a Code of Conduct for Health Research which, according to its webpage, may ‘guide researchers and administrative staff, reduce unnecessary fear relating to compliance and enhance data sharing for the purpose of stimulating progress in research’.\textsuperscript{49} Arguably, this has the potential to define and operationalise the regulatory space provided by Art 9(2)(j), and create a balanced and proportionate approach for the purpose of achieving the public interest in research while respecting the essence of the right to data protection and upholding suitable and specific measures to safeguard this fundamental right. As argued in this book, the careful calibrating requested in this operation is a difficult yet essential factor for biobanking. If unity in central areas is reached, a code of conduct for biobanking could prove a most valuable tool in the present fragmented legal landscape. However, striving for unity must be weighed against the benefit of allowing Member States some leeway to uphold national or regional traditions. The final assessment of ethical and legal viability of the individual research project in the future will also be conducted by research ethic committees (RECs) in the Member States. In order to gain general acceptance, the code of conduct must meet the ethical standards applied by these boards, taking into account the ambiguity resulting from Article 9(4) and Article 23 GDPR. Further, the international obligations discussed above (Sect. 2.3) must also be met. In order to achieve this, the stakeholders of the code of conduct must resolve the issues that the EU legislator was unable to overcome in the legislative process. A bottom-up approach may prove more successful.

6 Concluding Remarks: Can a Level Playing Field for Biobanks Develop?

One of the more salient objectives of the EU data protection reform leading to the enactment of the GDPR was to further align national laws on data protection. Nevertheless, as the GDPR allows for derogations via Member States law to such a high degree, it could be argued that it is a regulation in name only and that its form

\textsuperscript{47} The European Data Protection Board Guidelines 1/2019 on Codes of Conduct and Monitoring Bodies under Regulation 2016/679.

\textsuperscript{48} Ibid, p. 4.

\textsuperscript{49} http://code-of-conduct-for-health-research.eu. see also chapter by Lalova et al., in this book, Section 4.2.
in reality is more a directive. The regulatory regime for processing personal data in biobank research thus remains a mixed responsibility for the EU and its Member States.

The question of the relationship between the core data protection principles of the GDPR and national law that provides derogations has been analysed throughout this book. As has been seen, the regulatory differences in the Member States remain. However, the GDPR also introduces governance structures for administrative cooperation and the production of soft law documents to provide guidance for the interpretations of the GDPR and its core principles. Further, with the introduction of a new legal tool, the code of conduct, private entities and collaborative networks have also been invited to take part in the regulatory work. Thus, it may be argued that the harmonising factors in the area of research will be found in the area of soft law and governance tools rather than in the area of EU and Member State legislation.

This finding can be seen as contrary to one of the general features of fundamental rights law that derogations from a right should be set out in transparent and unequivocal rules enacted in a democratically legitimate manner. This notion is also recognised in the preamble of the GDPR:

Where this Regulation refers to a legal basis or a legislative measure, this does not necessarily require a legislative act adopted by a parliament, without prejudice to requirements pursuant to the constitutional order of the Member State concerned. However, such a legal basis or legislative measure should be clear and precise and its application should be foreseeable to persons subject to it, in accordance with the case-law of the Court of Justice of the European Union (the ‘Court of Justice’) and the European Court of Human Rights.

Further, as discussed above, the CJEU held in the Schrems case that there are limits to how far the right to data protection can be restricted via legally binding acts. Soft law documents and private-public governance tools can generally be said to lack the qualities of democratic legitimacy and transparency in comparison to legislative acts enacted by a parliament. However, the combination of practical need and lack of political will and/or legislative competence within the EU seems to have paved the way for these types of non-law solutions. One of the benefits of this softer form of developing a common understanding of law is that it does not call into question the formal transfer of powers from the national level to the supranational level, and therefore entails less of a commitment for the involved states. Moreover, as held by Mayrhofer and Prainsack, this is a common way of regulating international biobanking as non-legally binding agreements and soft law regularly emerge in the absence of a central regulator. Following the conclusions in the pan-European

---

50 Compare Article 52 of the Charter and Article 8.2 of the European Convention of Human Rights.
51 Recital 41 GDPR.
52 Case C-362/14 Schrems v Data Protection Commissioner, EU:C:2015:650, p. 94.
53 Reichel (2016), p. 186.
54 Spina (2011), pp. 249, 261.
55 Mayrhofer and Prainsack (2012), pp. 64, 70.
survey, chapter ‘Biobanking Across Europe Post-GDPR: A Deliberately Created Fragmented Landscape’ in this book, the assessment of the legal and ethical requirements will in the end be a question for RECs to resolve within their adjudication. The transparency and legal certainty of this adjudication would have benefitted from a fulfilment of the recommendation put forward in the 2012 Commission report, that the EU and its Member States ought to develop a consistent and coherent legal framework for biobanking that should protect participants’ fundamental rights, in particular in the areas of privacy, data protection and the use of human tissue in research.56

References

Busby H, Hervey T, Mohr A (2008) Ethical EU law? The influence of the European group on ethics in science and new technologies. Eur Law Rev 33:803–842
Dove ES (2015) Biobanks, data sharing, and the drive for a global privacy governance framework. J Law Med Eth 43(4):675–689
Giurgiu A, Larsen TA (2016) Roles and powers of national data protection authorities. Eur Data Prot Law Rev 2:342–352
Gottweis H et al (2012) Biobanks for Europe. A Challenge for Governance, Report of the Expert Group with Ethical and Regulatory Challenges of International Biobank Research. Directorate-General for Research and Innovation, European Commission, Brussels
Hijmans H (2016) The DPAs and their cooperation: how far are we in making enforcement of data protection law more European. Eur Data Prot Law Rev 2:362–372
Houwerzijl M (2014) ‘Regime shopping’ across (blurring) boundaries, regulating transnational labour in Europe: the quandaries of multilevel governance. Department of Private Law, Oslo University, Skriftserie 196, Oslo
Mayrhofer M, Prainsack B (2012) Being a member of the club: the transnational (self-) governance of networks of biobanks. Int J Risk Assess Manage 12:64–79
Reichel J (2016) Alternative rule-making within European bioethics – necessary and therefore legitimate? Tilburg Law Rev 21:169–192
Ruffert M, Steinecke S (2011) The global administrative law of science. Springer, Berlin
Slokenberga S, Reichel J, Niringiye R, Croxton T, Swanepoel C, Okal J (2019) EU data transfer rules and African legal realities: is data exchange for biobank research realistic? Int Data Priv Law 9(1):30–48
Spina A (2011) The regulation of pharmaceuticals beyond the state. In: Chiti E, Mattarella BG (eds) Global administrative law and EU administrative law. Springer, Berlin
Staunton C, Slokenberga S, Mascalzoni D (2019) The GDPR and the research exemption: considerations on the necessary safeguards for research biobanks. Eur J Hum Genet 1
Whitley SN (2016) Balanced ethics review. A guide for institutional review board members. Springer

56 Gottweis (2012), p. 6.
Open Access  This chapter is licensed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

The images or other third party material in this chapter are included in the chapter’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the chapter’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.